Court Opinion

ID: 4676699
Source: CourtListenerOpinion
Date Created: 2021-04-13 15:01:02.772135+00
Date Added: 2024-06-11T08:03:34.226347
License: Public Domain

Case: 20-1931    Document: 31     Page: 1   Filed: 04/13/2021

        NOTE: This disposition is nonprecedential.

   United States Court of Appeals
       for the Federal Circuit
                  ______________________

          IN RE: COLLEEN M. KAVANAGH,
                       Appellant
                ______________________

                        2020-1931
                  ______________________

     Appeal from the United States Patent and Trademark
 Office, Patent Trial and Appeal Board in No. 14/172,818.
                   ______________________

                  Decided: April 13, 2021
                  ______________________

     ERIK R. PUKNYS, Finnegan, Henderson, Farabow, Gar-
 rett & Dunner, LLP, Palo Alto, CA, for appellant.

    MEREDITH HOPE SCHOENFELD, Office of the Solicitor,
 United States Patent and Trademark Office, Alexandria,
 VA, for appellee Andrew Hirshfeld. Also represented by
 BENJAMIN T. HICKMAN, THOMAS W. KRAUSE, AMY J.
 NELSON, FARHEENA YASMEEN RASHEED.
                  ______________________

    Before DYK, MOORE, and O’MALLEY, Circuit Judges.
 O’MALLEY, Circuit Judge.
      Colleen M. Kavanagh (“Kavanagh”) appeals from a de-
 cision of the Patent Trial and Appeal Board (“Board”) af-
 firming an examiner’s final rejection of claims 1, 3–5, and
Case: 20-1931     Document: 31     Page: 2    Filed: 04/13/2021

 2                                            IN RE: KAVANAGH

 21–23 of U.S. Patent Application No. 14/172,818 (“the ’818
 application”) as obvious under 35 U.S.C. § 103. Ex parte
 Kavanagh, No. 2018-008867, 2020 WL 1951833 (P.T.A.B.
 Apr. 17, 2020) (“Board Decision”). We affirm.
                       I. BACKGROUND
     The ’818 application, entitled “System and Method for
 Obtaining Batch Information about a Product,” is directed
 to “[p]roviding test results for major food allergens at the
 time of purchase and/or consumption” to “help consumers
 with food allergies and intolerances avoid negative health
 consequences from cross contact.” J.A. 25. As the ’818 ap-
 plication explains, while food allergies are prevalent and
 potentially life-threatening, efforts to minimize cross-con-
 tact of food products are voluntary and vary by company.
 J.A. 18–21. And, although the Food and Drug Administra-
 tion (“FDA”) requires labeling for certain ingredients,
 “statements about potential cross contact from any of the
 major food allergens that are not in the ingredients are vol-
 untary.” J.A. 22. That voluntary labeling, coupled with
 non-standard wording among manufacturers, can lead to
 consumer confusion.
      The ’818 application states that a “superior step in con-
 sumer safety would be to test each batch of a food product
 for food allergens and make those test results available to
 consumers in a way that could help them be better in-
 formed when making immediate purchasing and consump-
 tion decisions.” J.A. 24. It then describes a wide variety of
 data that may be provided to the consumer, including in-
 formation on major allergens, uncommon allergens, ingre-
 dients, cross-contaminants, manufacturing processing
 agents, and information relevant to the environment in
 which the product was produced. J.A. 30–32. The applica-
 tion also describes several types of transmission methods,
 including quick response codes (“QR codes”), bar codes, ra-
 dio-frequency     identifying     chips,   and      Bluetooth
Case: 20-1931      Document: 31    Page: 3    Filed: 04/13/2021

 IN RE: KAVANAGH                                             3

 technologies. J.A. 33. A sample data transmission system
 is shown in Figure 1:

 Figure 1 depicts a food package (101) with a QR code (102)
 on the label. The consumer can scan the QR code using a
 smart phone (103), which then transmits the data through
 a network (104). J.A. 32–33. The QR data is received at a
 server (105). J.A. 33. The server accesses a memory (106)
 that contains batch data (107) for the food product. Id. In
 this example, the batch data includes the allergens dairy,
 peanut, gluten, and soy. The server then transmits the
 batch data back through the network to the consumer’s
 smart phone.
      Independent claim 1, the only claim at issue on appeal,
 is representative:
     A method for making a safer food product, said
     method comprising:
     selecting ingredients for said food product, said in-
     gredients being chosen from a group of ingredients
Case: 20-1931     Document: 31      Page: 4    Filed: 04/13/2021

 4                                             IN RE: KAVANAGH

     not known to cause an adverse reaction in a person
     having at least one food allergy or intolerance;
     manufacturing a batch of a food product, said man-
     ufacturing including combining said ingredients;
     packaging at least a portion of said combined ingre-
     dients into at least one package;
     providing an indicator for said batch on said pack-
     age;
     testing at least a portion of said batch for cross-con-
     tact, said testing occurring during or after manu-
     facture;
     storing results of said testing on a server computer;
     receiving an inquiry about said batch of said food
     product from a remote device, said inquiry includ-
     ing information derived, at least in part, from said
     indicator;
     obtaining the testing results of said batch in re-
     sponse to said inquiry; and
     transmitting said testing results of said batch to
     the device from which the inquiry was received,
     wherein said testing results are transmitted to the
     device from which the inquiry was made when the
     test results show that no measurable cross-contact
     has occurred and when the test results show that
     some measurable cross-contact has occurred.
 Board Decision, 2020 WL 1951833, at *1; J.A. 3.
     Three prior art references are relevant to this appeal:
 U.S. Patent Application No. 2015/0186966 (“Holman”),
 U.S. Patent Application No. 2013/0233919 (“van Waes”),
 and U.S. Patent Application No. 2008/0085343 (“Petty”).
 Holman teaches a method for preparing customized food
 products and packaging for consumers in order to meet
 their dietary needs and preferences. Holman’s customized
Case: 20-1931      Document: 31    Page: 5    Filed: 04/13/2021

 IN RE: KAVANAGH                                             5

 food preparation system includes manufacturing, packag-
 ing, and obtaining test results for a variety of food prod-
 ucts. J.A. 642; J.A. 648–49. Holman also discloses
 acquiring and storing user information, including prefer-
 ences, and test results for certain ingredients. J.A. 648. In
 Holman’s system, a consumer selects ingredients for a food
 product and the food product is manufactured and placed
 in customized packaging. The packaging provides various
 types of information, including a list of ingredients missing
 from the food product, the calorie content of the customized
 food item, or certain testing results. J.A. 639.
     van Waes discloses use of a data matrix code, such as a
 barcode, to track and trace food products. J.A. 568. In van
 Waes, a user scans the data matrix code using a smart
 phone and can then access data in a database. J.A. 572.
 Examples of information that may be included in the data-
 base include the name of a product, the date of storage, the
 recipe, the ingredients, or an “indication of risk of (cross-)
 contamination.” J.A. 572–73.
     Petty discloses preparing a low allergenic food bar and
 testing batches of the food bar during manufacture to en-
 sure that it substantially excludes compounds derived from
 the “Big 8” allergens (dairy products, eggs, shellfish, soy,
 fish, peanuts, tree-nuts, and wheat). J.A. 673; J.A. 678.
    The examiner rejected claim 1 as unpatentable over
 Holman in view of van Waes and further in view of Petty. 1

     1    The examiner also rejected claims 3–5 and 21–23
 as obvious over Holman, van Waes, and Petty, in combina-
 tion with additional prior art. On appeal, Kavanagh states
 that she “is not separately challenging the rejections of the
 dependent claims” such that “the fate of those claims will
 be [the] same as the fate of claim 1.” Appellant’s Br. 20 n.2.
 Because Kavanagh only challenges the rejection of claim 1,
 we limit our analysis to that claim.
Case: 20-1931     Document: 31     Page: 6    Filed: 04/13/2021

 6                                            IN RE: KAVANAGH

 Specifically, the examiner found that Holman’s disclosed
 method of customizing and packaging a food product en-
 compassed most of the steps of the claimed method, includ-
 ing: selecting ingredients, manufacturing a batch of food
 product, packaging the food product, providing a label, test-
 ing a portion of the batch, and storing the test results. J.A.
 312–13. The examiner relied on van Waes for the steps of
 receiving an inquiry about a food product from a remote
 device, obtaining the data, and transmitting it to the de-
 vice. J.A. 313–14. And the examiner found that “Petty
 teaches testing at least a portion of a batch for cross-con-
 tact, said testing occurring during or after manufacture.”
 J.A. 314.
     As to motivation to combine, the examiner explained
 that one of ordinary skill in the art would have recognized
 that making information accessible to the consumer via
 their mobile device (as taught by van Waes) would be an
 obvious improvement to Holman’s food product because it
 would allow the consumer to “track and trace” information
 about the product. Id. The examiner further found that it
 would have been obvious to one of skill in the art to modify
 the customized food batches and testing of Holman in view
 of van Waes to test the batches of customized food for cross-
 contamination during or after production (as taught by
 Petty) to ensure that the food product is free from aller-
 gens. J.A. 315.
      During examination, Kavanagh submitted several ar-
 ticles praising the claimed invention. J.A. 390–93, 412.
 The examiner noted that the evidence had not been sub-
 mitted with a declaration or affidavit, as the rules require.
 But the examiner explained that, even if she considered the
 evidence, it was insufficient to overcome the obviousness
 rejection. J.A. 412.
     Kavanagh appealed the examiner’s rejection to the
 Board and the Board affirmed. In doing so, the Board ex-
 pressly adopted the findings and rationale provided by the
Case: 20-1931      Document: 31    Page: 7    Filed: 04/13/2021

 IN RE: KAVANAGH                                            7

 examiner. Specifically, the Board explained that Holman
 discloses the majority of the claimed steps for manufactur-
 ing a safer food product, van Waes discloses obtaining and
 transmitting data about the food product, and Petty dis-
 closes testing the batch “for cross-contact, said testing oc-
 curring during or after manufacture.” Board Decision,
 2020 WL 1951833, at *2. The Board also affirmed the ex-
 aminer’s rationale for combining the references, as one of
 ordinary skill would have recognized that: (1) the teachings
 of van Waes would have improved the invention of Holman
 “by providing a detachable printed image for track and
 trace purpose of a product”; and (2) the teachings of Petty
 would have improved Holman in view of van Waes by batch
 testing, during or after production of the food product. Id.
     The Board then considered and rejected Kavanagh’s ar-
 guments. First, although Kavanagh argued that van Waes
 does not specifically disclose transmitting test results to
 consumers, the Board explained that the rejection was
 based on a combination of references. In particular, “van
 Waes discloses that the data regarding the food product is
 transmitted to the device via an accessible web page, and
 Petty was relied on as disclosing ‘testing for cross-contact
 occurring during or after manufacture of the food product.’”
 Id.at *3. The Board explained that any type of food product
 data, such as the specific test results of Petty, “would
 equally benefit from the type of data accessibility of van
 Waes.” Id. And the Board agreed with the examiner that
 the combination of van Waes and Petty sufficiently encom-
 passes the transmission of all test results regardless of
 whether there is some cross-contact detected or none.
     Next, the Board rejected Kavanagh’s argument that
 Holman does not teach or suggest testing a batch of food
 product for cross-contamination. Because the examiner’s
 rejection was based on a combination of the references,
 such that Holman’s testing of food products is modified by
 Petty’s teaching to test for cross-contact occurring during
 or after manufacture of the food product, the Board found
Case: 20-1931     Document: 31      Page: 8    Filed: 04/13/2021

 8                                             IN RE: KAVANAGH

 Kavanagh’s focus on individual references unpersuasive.
 Id.
      Finally, the Board considered the objective evidence of
 non-obviousness and agreed with the examiner that the ar-
 ticles submitted provided, at most, “scant evidence of some
 industry praise.” Id. at *4. The Board found that the arti-
 cles were conclusory and that Kavanagh failed to show that
 providing test results to a user was a long-felt need. Id. at
 *5. Nor did Kavanagh make any showing of a nexus be-
 tween the enthusiastic reactions in the articles and the
 claimed subject matter. Id. at *5–6.
     The Board found no error in the examiner’s rejection of
 claim 1 based on the combination of Holman, van Waes,
 and Petty.
     Kavanagh timely appealed to this court. We have ju-
 risdiction pursuant to 28 U.S.C. § 1295(a)(4)(A).
                        II. DISCUSSION
      Obviousness is a question of law based on underlying
 factual findings relating to “the scope and content of the
 prior art, differences between the prior art and the claims
 at issue, the level of ordinary skill in the pertinent art, and
 any objective indicia of non-obviousness.” Randall Mfg. v.
 Rea, 733 F.3d 1355, 1362 (Fed. Cir. 2013). Relevant objec-
 tive indicia include, among other things, commercial suc-
 cess, industry praise, long-felt but unmet need, failure of
 others, and unexpected results. See Apple Inc. v. Samsung
 Elecs. Co., 839 F.3d 1034, 1048, 1052–53 (Fed. Cir. 2016)
 (en banc) (citation omitted).
      We review the Board’s factual determinations for sub-
 stantial evidence and its legal determinations de novo.
 Celgene Corp. v. Peter, 931 F.3d 1342, 1349 (Fed. Cir. 2019).
 Substantial evidence is “more than a mere scintilla and
 means such relevant evidence as a reasonable mind might
 accept as adequate to support a conclusion.” Id. at 1349
 (citation omitted). Given this deferential standard, even if
Case: 20-1931      Document: 31    Page: 9    Filed: 04/13/2021

 IN RE: KAVANAGH                                             9

 “two different, inconsistent conclusions may reasonably be
 drawn from the evidence in record, an agency’s decision to
 favor one conclusion over the other is the epitome of a de-
 cision that must be sustained upon review for substantial
 evidence.” In re Jolley, 308 F.3d 1317, 1329 (Fed. Cir.
 2002).
     On appeal, Kavanagh argues that the Board erred
 when it: (1) rejected the claims despite the lack of any prior
 art disclosing the key element of the claimed invention—
 “providing to a consumer testing results”; and (2) over-
 looked important objective indicia of non-obviousness, in-
 cluding industry praise and long-felt need. Appellant’s Br.
 31–35. We address each issue in turn.
       A. The Prior Art Teaches the Steps of Claim 1
      First, the Board made sufficient factual findings to sup-
 port its obviousness conclusion, and those findings are sup-
 ported by substantial evidence. An obviousness analysis
 must account for the teachings of the prior art as a whole
 in light of the common sense and creativity of a person of
 ordinary skill in the art. See KSR Int’l Co. v. Teleflex Inc.,
 550 U.S. 398, 419–21 (2007). When a patent “‘simply ar-
 ranges old elements with each performing the same func-
 tion it had been known to perform’ and yields no more than
 one would expect from such an arrangement, the combina-
 tion is obvious” and unpatentable. Id. at 417 (quoting
 Sakraida v. Ag Pro, Inc., 425 U.S. 273, 282 (1976)).
      The ’818 application merely rearranges old methods of
 food manufacturing, packaging, and testing. Indeed, Ka-
 vanagh conceded during prosecution that the ’818 applica-
 tion “does not claim to have invented new methods of food
 manufacturing, packaging, or testing.” J.A. 287. Instead,
 it seeks to combine “these three known steps . . . into a new
 application of . . . old ideas.” Id. As the Board explained,
 however, the claimed method steps are disclosed in the
 three prior art references of record: Holman discloses food
 product testing, van Waes discloses data storage and
Case: 20-1931    Document: 31      Page: 10    Filed: 04/13/2021

 10                                           IN RE: KAVANAGH

 access, and Petty discloses testing for cross-contact during
 or after manufacture of the food product. Board Decision,
 2020 WL 1951833, at *4. The Board agreed with the exam-
 iner that a person of ordinary skill in the art would have
 been motivated to modify the food product testing of Hol-
 man to incorporate a barcode or QR code, as taught by van
 Waes, in order to track and trace a food product. Id. at *2.
 And the Board found that it would have been obvious to
 incorporate the results from cross-contact testing as dis-
 closed in Petty into the combination of Holman and van
 Waes, to ensure the food product is substantially free of al-
 lergens. Id. Substantial evidence supports the Board’s
 finding of motivation to combine.
     Kavanagh maintains that the Board failed “to identify
 any reference that teaches providing to a consumer testing
 results—especially testing results showing cross-contact.”
 Appellant’s Br. 34–35. Kavanagh also argues that Petty
 cannot be relied upon to show transmitting test results
 that show cross-contact. Id. at 36. But a finding of obvi-
 ousness “cannot be overcome ‘by attacking references indi-
 vidually where the rejection is based upon the teachings of
 a combination of references.’” Bradium Techs. LLC v.
 Iancu, 923 F.3d 1032, 1050 (Fed. Cir. 2019) (quoting In re
 Merck & Co., 800 F.2d 1091, 1097 (Fed. Cir. 1986)).
     Here, the Board explained that the obviousness rejec-
 tion was based on a combination of the prior art. In partic-
 ular, the prior art discloses that it was known to test a food
 product for cross-contact (Petty) and transmit data, includ-
 ing data about the risk of contamination (van Waes). As
 the Board explained, “any type of the stored/retrieved food
 product data, such as the specific test results of Petty,
 would equally benefit from the type of data accessibility of
 van Waes.” Board Decision, 2020 WL 1951833, at *3. Ac-
 cordingly, a skilled artisan would have found it obvious to
 transmit data about a food product, including data about
 cross-contact, to a consumer via a QR code.
Case: 20-1931      Document: 31   Page: 11    Filed: 04/13/2021

 IN RE: KAVANAGH                                          11

          B. Objective Indicia of Non-Obviousness
    Next, Kavanagh argues that the Board failed to
 properly weigh the objective indicia of non-obviousness.
 We disagree.
      Kavanagh submitted six articles praising the claimed
 invention as evidence of industry praise and long-felt, but
 unmet need. The articles included statements from “ex-
 perts in the field” calling the invention the “‘next genera-
 tion’ of food safety” and describing it as “so unique” and
 “Super Cool!” Board Decision, 2020 WL 1951833, at *4. As
 an initial matter, the Board noted that Kavanagh failed to
 properly submit the evidence to the examiner in the form
 of a declaration or affidavit. The Board nevertheless “fully
 considered the evidence” and concluded that it was insuffi-
 cient to show “that the claims would have been nonobvi-
 ous.” Id. at *5. Accordingly, despite Kavanagh’s argument
 to the contrary, the Board did not disregard the articles.
     As the Board explained, objective evidence of non-obvi-
 ousness must be relevant to the subject matter as claimed,
 and “there must be a sufficient relationship between that
 evidence and the patented invention.” In re Paulsen, 30
 F.3d 1475, 1482 (Fed. Cir. 1994). The Board found that
 nothing in the articles Kavanagh submitted tied the praise
 of the invention or its success to the claimed features.
 Board Decision, 2020 WL 1951833, at *5–6. And the Board
 agreed with the examiner that the articles contained “gen-
 eral comments by other entities in the field” that were both
 conclusory and lacked “persuasive factual support.” Id. at
 *5. Substantial evidence supports the Board’s findings.
     The Board further found that Kavanagh failed to pro-
 vide concrete evidence of a long-felt, but unmet need. Id.
 Kavanagh argues that the Board applied an incorrect
 standard in requiring her to prove that others attempted
 to create the claimed process, but failed. Appellant’s Br.
 48. Not so. The Board merely explained that “absence of
 the specific claimed process does not conclusively prove
Case: 20-1931    Document: 31      Page: 12    Filed: 04/13/2021

 12                                           IN RE: KAVANAGH

 that there was a long felt need for that method of manufac-
 turing food products. Nor does the absence of the claimed
 method show that others attempted to create such a pro-
 cess, but failed at doing so.” Board Decision, 2020 WL
 1951833, at *5. Instead, we have said that long-felt need
 involves a showing of “an articulated identified problem
 and evidence of efforts to solve that problem.” Tex. Instru-
 ments Inc. v. U.S. Int’l Trade Comm’n, 988 F.2d 1165, 1178
 (Fed. Cir. 1993).
     Kavanagh maintains that the articles describe the in-
 vention as solving long-standing food safety concerns about
 cross-contact. While that may be true, the Board found
 that the evidence failed to show that the claimed process—
 “testing a portion of a manufactured batch of food and
 providing the test results to a user”—was a long-felt need.
 Board Decision, 2020 WL 1951833, at *5. As the govern-
 ment points out, moreover, “there are a multitude of rea-
 sons why manufacturers might have been incentivized
 NOT to test their products and publicize their results, in-
 cluding liability for inaccurate results and the cost of test-
 ing and publicizing.” Appellee’s Br. 23. Accordingly, the
 absence of the claimed process may have had nothing to do
 with a long-felt, but unmet need.
     We give the Board “broad deference” in its weighing of
 objective evidence of non-obviousness. In re Inland Steel
 Co., 265 F.3d 1354, 1366 (Fed. Cir. 2001). On this record,
 we discern no error in the Board’s finding that Kavanagh’s
 limited evidence of industry praise and long-felt need was
 not entitled to substantial weight.
                       III. CONCLUSION
     We have considered Kavanagh’s remaining arguments
 and find them unpersuasive. For the reasons discussed
 above, we affirm the Board’s decision rejecting claims 1, 3–
 5, and 21–23 of the ’818 application as obvious.
                         AFFIRMED
Case: 20-1931      Document: 31   Page: 13   Filed: 04/13/2021

 IN RE: KAVANAGH                                         13

                            COSTS
 No costs.